Lung transplantation is the treatment of choice for end-stage pulmonary diseases. A limited donor supply has resulted in 4000 patients on the waiting list. Currently, 10-20% of donor organs offered for transplantation are deemed suitable under the selection criteria, of which 15-25% fail due to primary graft dysfunction (PGD). This has spawned efforts to reexamine the current selection criteria as well as search for alternative donor lungs selection criteria. In this study, we attempt to further our understanding of PGD by observing the changes in gene expression across donor lungs that developed PGD versus those that did not. From our analysis, we have obtained differentially expressed transcripts that were involved in signaling, apoptosis and stress-activated pathways. Results also indicate that metallothionein 3 was over expressed in lungs that didn't develop PGD. This is the first such attempt to perform expression profiling of actual human lungs used for transplantation, for the identification of a molecular signature for PGD.
Introduction
Lung transplantation has gained widespread acceptance for the treatment of end-stage pulmonary diseases. However, two significant problems in clinical lung transplantation are a major shortage of donor organs and the incidence of primary graft dysfunction (PGD). PGD is a severe allograft ischemia-reperfusion (I/R) injury syndrome occurring in the h following transplantation. Improvements in operative techniques, donor lungs management and immunosuppressive protocols have decreased perioperative mortality to below 10% at most experienced lung transplant centers (1, 2) . The 1-and 5-year survival rates have improved to 76% and 49%, respectively (1) . These results, however, continue to lag behind those achieved for other solid organ transplants. The occurrence of PGD after lung transplantation significantly increases the duration of mechanical ventilation, hospital length of stay and short-term mortality after lung transplantation (3) . Survivors of PGD have a significantly protracted recovery with impaired physical function up to 1 year after transplantation and an increased risk of death extending beyond the first year after transplantation (3, 4) .
The current criteria used to evaluate potential donor lungs appear to be inadequate at predicting how these lungs will function posttransplantation (5) (6) (7) . Donor organs are evaluated for lung transplantation on the basis of criteria that are primarily historically founded and largely arbitrary (8) . Relatively crude measures of lung function such as chest radiography, arterial oxygen tension in blood gases, and bronchoscopy are currently used to assess the quality of potential donor lungs. That these tools are inadequate in evaluating organs from prospective donors is evidenced by two recent developments. First, the liberalization of the selection criteria and the use of 'marginal' donor lungs by many centers have not had a negative impact on outcome after transplantation (9) (10) (11) . A recent study showed no significant difference in a number of indices for infection and inflammation between donor lungs that were accepted and rejected for transplantation (7) . Second, the incidence of PGD or I/R injury after transplantation remains unchanged at 15-25% despite the increased use of marginal donor lungs and improvements in all areas of lung transplantation (2, 4, 12) . While recent studies have identified donor age and recipient diagnosis of primary pulmonary hypertension (PPH) as risk factors for the development of PGD, the aetiology of PGD in most cases after transplantation is unknown and thought to be due to complex interactions between donor lung and recipient immune system (13, 14) .
A limited donor supply has dramatically increased the waiting time for transplant recipients. Currently, only 10-20% of deceased donor organs offered for transplantation are judged to be acceptable under the current selection criteria (15) . The results of the above mentioned studies suggest that there may be complex, occult biological factors present in donor lungs which contribute to the development of PGD that are not detected by the current donor organ evaluation. Gene expression profiling is a powerful, high-performance tool of molecular biology that allows the analysis of the levels of expression of thousands of genes simultaneously. It has been previously used to study gene transcripts involved in I/R injury using a rat model (16) . To the best of our knowledge, however, this is the first report where gene expression profiling has been done on actual human lungs used for transplantation, along with the application of bioinformatics techniques to find a set of transcripts that are differentially expressed between unsuitable and suitable donor lungs. Our main objective in this study is to obtain a set of genes involved in PGD. This objective would provide greater insights into the mechanisms of PGD as well as extend the work of Yamane et al. (16) .
Materials and Methods

Donor lung sampling
From August 2003 to January 2005, 80 transplants were performed in our program at Washington University School of Medicine. Three of these were excluded from the study, as one was a single lung transplant, another was a heart-lung transplant, while the third was a combined coronary artery bypass graft with lung transplant, and nine patients did not give consent. This resulted in biopsies of 68 donor lungs used for bilateral sequential lung transplantation. The biopsies were obtained from the anterior right middle lobe or lingula immediately prior to cold-flushing. Of the remaining biopsies, some samples were excluded due to technical errors or complexities during expression profiling, resulting in a net total of 50 biopsies being used for the study. Five lungs were considered marginal donor lungs based on them portraying one or more of the following conditions-either PaO 2 in arterial blood gas <300 on 100% inspired oxygen, or smoking history >20 packyears or donor age >55. These samples were immediately snap-frozen in liquid nitrogen and then stored in a −70
• Celsius freezer until used for 
RNA isolation
cDNA synthesis and gene expression profiling
This study used commercially available high-density microarrays (Affymetrix, Santa Clara, CA) that produce gene expression levels on 22278-probe sets (Affymetrix Human Genome U133Av2.0 Array). Each donor lung biopsy was analyzed on a different GeneChip. Preparation of cDNA, hybridization and scanning of the arrays were performed according to the manufacturer's instructions. The arrays were scanned using the Affymetrix GeneArray scanner. Image analysis was performed with the Affymetrix GeneChip software. We also performed a quality control test on the dataset using the R package 'affyQCReport' (17) and the results indicated that the data quality is good.
Data
The data from all the 50 gene chips was normalized using GCRMA (18) . This normalization tool is available in Bioconductor. The 50 donor lung samples were divided into two groups-those that developed PGD after transplantation (PGD positive) and those that did not (PGD negative). PGD was defined as T0 Grade III dysfunction according to International Society for Heart and Lung Transplantation criteria, that is, a ratio (referred to as the P/F ratio) of partial pressure of arterial oxygen (PaO 2 ) to fraction of inspired oxygen (FiO 2 ) less than 200 in the first arterial blood gas in the intensive care unit after transplantation (generally 4-6 h after actual reperfusion) (19) . Sixteen samples were classified as PGD positive according to this definition and the remaining 34 were PGD negative.
Transcripts selection
We then proceeded to the next step in our study-the identification of differentially expressed transcripts. The objective was to find a set of differentially expressed transcripts/probes that could be used as a molecular signature for the condition. In this study, we used two packages for the identification of differentially expressed transcripts-RankGene (genomics10.bu.edu/yangsu/rankgene/) (20) and significance analysis of microarrays (SAM) (www-stat.stanford.edu/∼tibs/SAM/) (21).
RankGene is a program for analyzing gene expression data, feature selection and ranking genes based on the predictive power of each gene to classify samples into functional or disease categories. It supports eight different measures for quantifying a gene's ability to distinguish between classes. For our analysis, we used the t-statistics measure of predictability. The tstatistic value is a score for each gene's ability to discriminate between the two classes. RankGene ranks genes according to the decreasing order of the absolute value of the t-statistic for each gene. The group of top genes from this ranked list is considered to be the most informative for distinguishing between the classes. SAM is open-source software that identifies differentially expressed genes based on the change in gene expression relative to the standard deviation of repeated measurements (21) . It uses the false discovery rate (FDR) and q-value method presented in (22) to select genes. As microarrays result in the measurement of several thousand probes across different conditions, the individual p-values are not a good measure of significance. This is because when testing for differential expression across the different conditions, each gene is considered independently from one another. This can result in a large number of false positives. The q-value is used to correct for multiple testing. It is analogous to the p-value and is corrected, through a permutation process, for the variability of the expression data. The q-value of a transcript is the FDR for the transcript list that includes that transcript and all transcripts that are more significant. SAM also provides the tail strength (TS) value, which measures the deviation of each p-value from its expected value. Therefore, large
Ray et al.
positive TS values indicate evidence against the null hypothesis, that is, there are more small p-values than one would expect by chance (23) .
We first ran RankGene on the complete set of probes. Since we were interested in a small set of the most highly differentially expressed transcripts, we chose to take the top 100 transcripts from the ranked list for further analysis. On this list of 100 differentially expressed transcripts, we applied SAM. SAM displayed 81 differentially expressed transcripts based on a FDR of 0% and a TS of 92.7%. The 81 probes were mapped to gene names using DAVID (http://niaid.abcc.ncifcrf.gov/tools.jsp). After averaging the values of and removing multiple probes mapping to the same gene name, 23 upregulated and 42 downregulated transcripts were obtained. These sets of up and down regulated transcripts were used for further analysis in Ingenuity Pathway Analysis (IPA) software.
Pathway analysis
IPA (www.ingenuity.com) was used to perform pathway analysis on the two sets of differentially expressed transcripts-upregulated and downregulated, to identify networks of genes that are known to interact functionally. IPA uses the Ingenuity Pathways Knowledge Base (IPKB), which contains large amounts of individually modeled relationships between objects (e.g. genes, proteins and mRNAs) to dynamically generate significant biological/gene expression networks and pathways. The identified differentially expressed transcripts from our analysis that are mapped onto the IPKB are called 'focus genes.' These are used as starting points for building the networks. IPA consists of genes that have functions assigned to them and are in published literature. First, IPA queries the IPKB for interactions between the focus genes and all other genes stored in IPKB and then generates a set of networks/pathways with a maximum of 35 genes. A p-value for each network is calculated according to the user's list of differentially expressed genes. This is accomplished by comparing the number of focus genes that are present in a given pathway, relative to the total number of occurrences of those genes in all pathways stored in IPKB. The score of the network is shown as the negative logarithm of the p-value, indicating the likelihood of the focus genes in a network being found together by random chance. In our study, we further analyzed networks that had a network score of 10 or higher. IPA consists of only those genes that have functions assigned to them and the relationships among them are in published literature. If genes do not have any known functions assigned to them, they do not become focus genes.
Results and Discussion
The definition of PGD used in this study was T0 Grade III PGD as described by the International Society for Heart and Lung Transplantation consensus statement on the definition of PGD (19) . In this statement, any time between immediately posttransplant (T0, ideally defined as arrival in the ICU, within 6 h postreperfusion) and 72 h after transplantation (T72) can be used to measure blood gases and define PGD. Although definitions of PGD at later time points may more accurately reflect outcomes after transplantation, they may also be potentially affected by other postoperative factors such as overall fluid balance or presence of infection. Our objective in this study was to identify biologic risk factors in donor lungs that may contribute to PGD and therefore we felt that this was most purely measured at T0, where lung function may most clearly reflect the status of the donor lung at the time ofrecovery of organs. Furthermore, data from our institution suggests that PGD as early as T0 is associated with the development of bronchiolitis obliterans syndrome (chronic rejection) (24) .
The characteristics of the donor lungs are depicted in Table 1 . The operative factors and the outcome of patients with PGD versus those without are shown in Tables 2  and 3 , respectively. Despite other studies correlating donor age and recipient diagnosis of PPH with PGD, we have not seen a significant correlation in our samples. Although, cardiopulmonary bypass (CPB) seemed to be significant, it could also occur as a result of PGD rather than be a causative factor of PGD. SAM analysis resulted in 81 differentially expressed transcripts, which resolved into 65 unique genes using DAVID at the time of writing this article. A flowchart depicting the sequence of analysis is shown in Figure 1 .
Pathways and gene products involved in PGD
The upregulated transcripts were analyzed using the IPA software. There were 23 upregulated transcripts, of which 13 were focus genes. Focus genes are the genes that map onto the IPKB. The network generated from these genes is shown in Figure 2 . Figure 1 : Sequence of analysis undertaken in this study. Gene expression profiling was conducted on 50 lung samples. The transcripts were ranked using RankGene in descending order of their t-statistic and the top 100 were selected for further analysis. The set of 100 transcripts was analyzed using SAM and it output 81 differentially expressed transcripts. These 81 probes were mapped to gene names using DAVID. After averaging the values of and removing multiple probes mapping to the same gene name, 23 upregulated and 42 downregulated transcripts were obtained. Of the 23 upregulated transcripts, 13 became focus genes in IPA and of the 42 downregulated, 11 were focus genes in IPA.
Network 1 (Legend in Figure 6 ) primarily centers on tumor protein p53 (TP53). The focus genes are shown in solid shaded shapes and more details on these nodes are given in the supplementary material (Table 1 ). Figure 3 shows the location of the different gene products and the canonical pathways present in Network 1. Pathways related to apoptosis and cell signaling are present, as over 50% of the donor lungs were involved in trauma. A few transcripts identified are also cancer-related genes. There is growing evidence of genetic parallels between lung development and several types of cancer (25, 26) . The authors of (27) have shown that Wnt signaling, cell cycle and apoptosis pathways play important roles in lung development. We also have noticed an increased presence of genes in these pathways in our study ( Figure 3 ).
Next, we analyzed the 42 downregulated transcripts using IPA, and obtained 11 focus genes. The network created from these 11 genes is shown in Figure 4 . Network 2 shows a lot of activity around beta-5 integrin (ITGB5) and GRB2-associated binding protein 2 (GAB2). The focus genes are shown in solid shaded shapes, and further description of these nodes is given in the supplementary material (Table 2) . We observe similar pathways, as the ones present in Network 1, in Network 2. This is expected, as a pathway can consist of up and downregulated genes.
Both the networks show the presence of nuclear factorKB (NFKB), stress-activated protein kinases NH 2 -terminal Jun kinase (SAPK/JNK) and p38 mitogen-activated protein kinase (MAPK) signaling pathways. NFKB plays a vital role in mediating immune and inflammatory responses and apoptosis. It regulates the expression of a large number of genes. Many of the gene products regulated by NFKB in turn activate NFKB, such as vascular endothelial growth factor (VEGF), and receptor for advanced glycation end product (RAGE). Activation of NFKB involves the phosphorylation-induced, proteasome-mediated degradation of the inhibitory subunit-inhibitory protein KB. This protein is phosphorylated by an upstream serine kinase, which, in turn is phosphorylated and activated by additional upstream serine kinases. SAPK/JNK are the members of the superfamily of MAP serine/threonine protein kinases. This family also includes p38 MAP kinases (p38 MAPK) and extracellular signal-related kinases (ERK) (28) . JNK/SAPK and p38 MAPK are known as stress-activated kinases, and are responsive to numerous exogenous and endogenous stress-inducing stimuli, such as reactive oxygen species (ROS), oxidative stress, osmotic stress, proinflammatory cytokines, heat shock and ultraviolet irradiation. Oxidative stress is defined as a persistent imbalance between the production of highly reactive molecular species (primarily oxygen and nitrogen) and antioxidant defenses, finally resulting in tissue damage. There is evidence in literature that NFKB, SAPK/JNK and p38 MAPK signaling pathways are stress-sensitive intracellular signaling systems, activation of which results in the increased expression of numerous gene products that cause cellular damage (29) .
Gene products associated with stress-activated pathways emerged from both our study as well as the study in the rat model for I/R injury (16) . As suggested by the recent articles in Nature Biotechnology by the MicroArray Quality Control (MAQC) project (30) , it is better to focus on pathways and broad functional relationships, rather than on individual genes. We have observed a good deal of overlap in the functional categories/pathways of the identified transcripts. As not all animal model studies translate well into human analysis, our investigation takes the study performed by (16) a step further by performing the analysis on human samples and showing consensus.
An exciting observation was that the metallothionein (MT) family of gene products was identified as being Table 1 in the supplementary information. The legend for this figure is Figure 6 . upregulated in the lungs that did not develop PGD. In the work by Yamane et al. (16) , MT levels of expression are much lower in the microarray when compared to most of the other genes considered significant. However, RT-PCR confirms that it does have an increased expression. Hence, the rat study as well as ours does confirm the elevated expression of MT.
MTs are low molecular weight, intracellular zinc-binding proteins with antioxidant properties. The MT family consists of 3 isoforms-MT1, MT2 and MT3. We extracted the MT3 pathway from Network 1 (see Figure 5 ). Although the exact mechanism by which MT3 operates is not well known, there are a few studies that have explained the possible roles of MT, especially MT1 and MT2. A recent study has shown that MTs have positive effects during the early phase of islet transplantation (31) . Another study has shown that the MT gene is upregulated in wound margins, particularly, in regions of high mitotic activity (32) . These observations reflect its role in promoting cell proliferation and re-epitheliation. Furthermore, selected growth factors may modulate MT gene expression and hence, the ability of cells to proliferate (32) . As can be seen from Figure 6 , MT3 is connected to NFKB1. In human fibroblasts, NFKB protein consisting of p50 [NFKB1] and of p65 v-rel reticuloendotheliosis viral oncogene homolog A (RELA) increases expression of human MT3 mRNA. There is also an indirect relationship between MT3 and epidermal growth factor (EGF). EGF is involved in EGF signaling, ephrin receptor signaling, neuregulin signaling, and NFKB signaling. EGF's role in the cell is proliferation, migration, mitogenesis, apoptosis, growth, chemotaxis, transformation, stimulation, S phase and differentiation. Several other articles have also shown that MT positively regulates the cellular level and activity of NFKB (33, 34) . Recent work by St. Croix et al. (35) has also shown the protective role of MT in acute lung injury. Cells deficient in MT1 and MT2 have shown increased sensitivity to apoptosis (36) . Other work suggests that under inflammatory conditions, MT supports beneficial movement of leukocytes to the inflammation site (37) . In vitro experiments have shown that modest increase in MT levels still provides protection against oxidative stress (38) . Another interesting study in human fibroblasts demonstrated that MT3 can scavenge free oxygen radicals thereby providing protection from oxidative stress (39) . All this research on MT suggests that it is a valuable gene and should be analyzed in extensive detail in the context of PGD.
The study design affects the kind of questions that can be posed as well as the quality of answers. As this was a pilot study to test the feasibility of the approaches, we restricted it to only a few samples. The conclusions in this article are specific to the dataset analyzed. Furthermore, we did not have enough tissue material to perform RT-PCR to validate the microarray results. We hope that this research would motivate and warrant the need for a larger study with microarray validation tools. Moreover, an animal model would allow for more samples to be taken at different time points, which would further strengthen the study. An interesting strategy would be to perform a random sampling of different regions of the lung and subject it to microarray analysis. This was not done in this study due to three reasons--(1) taking multiple samples from a donor lung when the primary objective is transplantation is difficult to justify (2) taking samples from different regions of the lung necessitates the need for a larger sample set in order to reduce variance and increase statistical power and, finally, (3) it was convenient to take a biopsy from the lingula or anterior right middle lobe as opposed to other regions, without compromising the amount of time the lung is kept without function assigned to them as yet. Further research into the functions of these transcripts will also provide some insight into their role in PGD.
Conclusion
PGD is the single most significant factor in determining perioperative morbidity and mortality and has a devastating impact on outcome following lung transplantation. Perioperative mortality rates for those with clinically significant PGD are as high as 40-60%. Furthermore, those that survive complications of PGD endure lengthy hospitalization periods and a protracted and often compromised recovery, evidenced by inferior exercise tolerance and pulmonary function testing and the inability to achieve independent lifestyles. Moreover, PGD is now being identified as a risk factor for acute and chronic rejection.
The incorporation of biological markers into donor organ evaluation will have a significant impact on outcomes after lung transplantation by identifying lungs at risk for the development of PGD posttransplant, which would allow pretreatment of these high-risk organs or matching of these organs to relatively lower-risk recipients. Further identification and elucidation of genetic markers in donor lungs associated with PGD could have a significant impact on lowering the incidence and preventing the morbidity and mortality of PGD after lung transplantation.
